Photo of Sikhulile Moyo by Emily Makowski
Working Together to Fight Disease
Spotlighting Emily Makunike-Shava, MBChB, Msc: Q&A
Passengers register their information on arrival at Sir Seretse Khama International Airport in Gaborone, Botswana, June 3, 2020. Xinhua via Getty/Photo by Tshekiso Tebalo
Inside The Lab That Identified Omicron
Tsepamo Study Coordinator, Modiegi Diseko updating the Ministry of Health and Wellness on study progress
BHP Updates MOHW on Tsepamo Study Progress
BHP Board Chairman and Principal Investigator for Tatelo Study presenting study findings at the Ministry of Health
Dual bNAb HIV Treatment Well Tolerated In Children
Dr Moyo wins German Africa Award
Dr Moyo wins German Africa Award
Dr Nabila Youssouf, InterCARE Study Manager
Ponatshego and Youssouf Receive Grant Awards
Tsepamo Study Coordinator, Modiegi Diseko
Botswana Records Low Adverse Birth Outcomes Following Lockdown
Sikhulile Moyo, the laboratory director at the Botswana-Harvard AIDS Institute Partnership and a research associate with the Harvard T.H. Chan School of Public Health, headed the team that identified the omicron variant.
The Scientist In Botswana Who Identified Omicron Was Saddened By The World's Reaction
On November 19 scientists at the Botswana Harvard HIV Reference Laboratory first discovered the variant Omicron [Courtesy: Botswana Harvard Partnership]
Inside the Botswana Lab that Discovered Omicron
Botswana Researcher Who Sequenced Omicron Urges More Genomic Surveillance, Vaccinations In Africa
The main building of the Harvard-Botswana partnership is in Gaborone, Botswana.BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP
How A Harvard-Affiliated Lab In Botswana Became The First To Identify The Omicron Variant
Dr Sikhulile Moyo named to TIME's annual TIME100 list of the 100 most influential people in the world" as a notification
a
New Cryptococcal Meningitis Treatment as Good as Current Care with far fewer serious side effects
a
Positive AMBITION-cm Study Findings on the Treatment of HIV-Associated Cryptococcal Meningitis (CM).
a
Long-Acting Injectable Cabotegravir Proves Superiority over Daily Oral Truvada for HIV Prevention in Women
a